The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

An early-phase trial found that a personalized vaccine targeted and destroyed cancer cells in nine patients with advanced kidney cancer, effectively wiping out the disease and keeping it at bay ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

Jefferies lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $42 from $53 and keeps a Buy rating on the shares. For the FY24 ...